RxDoctor Payments Data

Eduardo Colon Melendez

Internal Medicine · Ponce, PRNPI 1023678760

Payments from drug & device makers

$4,995in general payments, 2019–2025

Across 133 payments — averaging $37.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$755
  • AstraZeneca$580
  • Johnson & Johnson$408
  • Bayer$339
  • Lilly USA, LLC$323
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$322
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$4,94599%
  • Gifts$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,995 in reported general payments places this provider in the 90th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$8,557
Medicare patients
12
Services billed
104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$26,821
JardianceEmpagliflozin35$23,817
FarxigaDapagliflozin Propanediol17$14,560
BrilintaTicagrelor23$13,001
SynthroidLevothyroxine Sodium83$9,183
Atorvastatin Calcium191$2,155
Omega-3 Acid Ethyl Esters12$1,599
Metoprolol Succinate101$1,521
Humulin 70-30Insulin Nph Hum/Reg Insulin Hm21$1,404
LantusInsulin Glargine,hum.Rec.Anlog12$1,182
Gabapentin75$1,094
Famotidine82$912
Pantoprazole Sodium80$819
Losartan Potassium69$763
Omeprazole40$699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$580$27,56140 claims
PfizerEliquis$89$26,82141 claims
Boehringer IngelheimJardiance$305$23,81735 claims
AbbVieSynthroid$145$9,18383 claims
Lilly USA, LLCHumulin 70-30$323$1,40421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →